Want to see IKT full AI Analyst Report?
Inhibikase Therapeutics (IKT) Stock Statistics & Valuation Metrics
Total Valuation
Inhibikase Therapeutics has a market cap or net worth of $216.28M. The enterprise value is $195.36M.
- Market Cap
- $216.28M
- Enterprise Value
- $195.36M
Share Statistics
Inhibikase Therapeutics has 139,535,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 139,535,900
- Owned by Insiders
- 16.63%
- Owned by Institutions
- 15.02%
Financial Efficiency
Inhibikase Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -30.06%.
- Return on Equity (ROE)
- -0.28
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -30.06%
- Return on Capital Employed (ROCE)
- -0.30
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.38M
- Employee Count
- 35
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Inhibikase Therapeutics is -3.24. Inhibikase Therapeutics’s PEG ratio is -0.03.
- PE Ratio
- -3.24
- PS Ratio
- 0.00
- PB Ratio
- 1.75
- Price to FCF
- -4.99
- Price to Operating Cash Flow
- -6.31
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Inhibikase Therapeutics had revenue of 0 and earned -48.26M in profits. Earnings per share was -0.49.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -51.97M
- Pretax Income
- -48.26M
- Net Income
- -48.26M
- EBITDA
- -53.29M
- Earnings Per Share (EPS)
- -0.49
Cash Flow
In the last 12 months, operating cash flow was -42.61M and capital expenditures -452,023, giving a free cash flow of -43.06M billion.
- Operating Cash Flow
- -42.61M
- Free Cash Flow
- -43.06M
- Free Cash Flow per Share
- -0.25
Dividends & Yields
Inhibikase Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -20.11%
- Earnings Yield
- -22.63%
Stock Price Statistics
- Beta
- 1.84
- 52-Week Price Change
- 4.76%
- 50-Day Moving Average
- 2.08
- 200-Day Moving Average
- 1.94
- Relative Strength Index (RSI)
- 33.21
- Average Volume (3m)
- 574.51K
Important Dates
Inhibikase Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Inhibikase Therapeutics as a current ratio of 21.70, with Debt / Equity ratio of 0.00%
- Current Ratio
- 21.70
- Quick Ratio
- 21.70
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.61
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Inhibikase Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Inhibikase Therapeutics EV to EBITDA ratio is -2.94, with an EV/FCF ratio of -4.25.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.94
- EV to Free Cash Flow
- -4.25
- EV to Operating Cash Flow
- -4.29
Balance Sheet
Inhibikase Therapeutics has $159.02M in cash and marketable securities with $0.00 in debt, giving a net cash position of $159.02M billion.
- Cash & Marketable Securities
- $159.02M
- Total Debt
- $0.00
- Net Cash
- $159.02M
- Net Cash Per Share
- $1.14
- Tangible Book Value Per Share
- $0.88
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Inhibikase Therapeutics is $4.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $4.88
- Price Target Upside
- 216.56% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 59.89%
Scores
- Smart Score
- 3
- AI Score
- 46
